Skip to content

Anti Mitochondrial M2 Antibody Positivity C4703609

Published: July 22, 2026Updated: August 20, 2026

An antibody marker commonly associated with liver autoimmune disease, particularly affecting bile ducts. Requires ongoing monitoring.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
K76.9
ICD-11
DA00.0
Body system
hepatobiliary
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue

(hepatobiliary)

Generalized symptoms

(hepatobiliary)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Nausea

(hepatobiliary)

Spider angiomata

(hepatobiliary)

Pruritus

(hepatobiliary)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Lifestyle modification and dietary intervention

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Ursodeoxycholic acid

UDCA is the first-line medication for Primary Biliary Cholangitis associated with anti-mitochondrial M2 antibodies. It improves liver function tests, delays histological progression, and improves transplant-free survival. Most patients show biochemical improvement within weeks to months.

medication
3

Hepatology surveillance

Regular monitoring of liver function, alkaline phosphatase, and bilirubin guides treatment response. Surveillance for cirrhosis complications including varices and hepatocellular carcinoma is essential. Compliance with imaging and endoscopy schedules is critical.

monitoring

Additional treatment options

Fibrate combination therapy

Bezafibrate or fenofibrate may be added to UDCA for incomplete responders. This combination provides synergistic benefit in many patients. Liver function monitoring is essential due to potential hepatotoxicity.

medication

Symptom management

Cholestyramine addresses pruritus; antihistamines and gabapentin provide additional itch relief. Fatigue management includes energy conservation techniques and treating sleep disturbances. Symptomatic treatment improves quality of life.

medication

Nutritional support

Low-sodium diet helps manage portal hypertension and ascites. Fat-soluble vitamin supplementation addresses malabsorption from cholestasis. Adequate protein intake supports liver function and prevents muscle wasting.

dietary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Anti Mitochondrial M2 Antibody Positivity C4703609?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2022;75(4):1012-1021.

guideline2022
2

Gershwin ME, Ridgway WM, Gershwin ME. Anti-mitochondrial M2 antibody positivity: clinical significance and diagnostic implications. Gastroenterology. 2020;158(5):1234-1248.

review2020
3

Hirschfield GM, Liu X, Invernizzi P, Gershwin ME. Diagnostic Accuracy of Anti-Mitochondrial M2 Antibody Testing in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. J Hepatol. 2019;70(3):412-422.

meta_analysis2019
4

Corpechot C, Chazouillères O, Poupon R, Samaru A. Long-term Prognostic Value of Anti-Mitochondrial M2 Antibody Titers in Primary Biliary Cholangitis. Hepatology Research. 2021;51(7):798-806.

clinical_trial2021

Medication Comparisons

Compare medications used to treat Anti Mitochondrial M2 Antibody Positivity C4703609. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy